Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings is positioned to be a leader in cardiac monitoring, with its innovative technology and partnerships driving steady revenue growth. The company's strong fundamentals, including a large addressable market and increasing penetration in the primary care physician channel, make it a compelling investment opportunity. In addition, the company's progress in remedying the FDA warning letter and its successful launch of a next-generation algorithm are positive indicators for future growth. However, potential risks such as increased competition and negative reimbursement developments should be monitored.

Bears say

iRhythm Holdings is expected to face operational hiccups and risks surrounding their DoJ inquiry and FDA warning letter, potentially leading to negative consequences. In addition, the delay in releasing their Gen 3 algorithm due to resource prioritization for cybersecurity may lead to missed growth opportunities in the long-term. The company's valuation at 6x projected 12-24 month revenue estimate also raises concerns about the company's potential for profitability and market saturation.

iRhythm Technologies (IRTC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 12 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $179.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $179.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.